Pilot Trial of Two Dose Levels of Thymoglobulin as Part of a Myeloablative-Conditioning for a Human Leukocyte Antigen (HLA) Identical Matched Related Donor (MRD) Stem Cell Transplant (SCT) With Cyclosporine (CSa) as Post-transplant Graft vs. Host Disease (GvHD) Prophylaxis
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label
Incidence of Grade II to IV acute GvHD in the first 100 days after transplant.
100 days
Yes
Medical Monitor
Study Director
Genzyme
United States: Food and Drug Administration
SMC-101-1026
NCT00088543
March 2004
April 2006
Name | Location |
---|---|
Washington University School of Medicine | Saint Louis, Missouri 63110 |
Cancer Center at Hackensack University Medical Center | Hackensack, New Jersey 07601 |
University of Pennsylvania | Philadelphia, Pennsylvania 19104 |
Duke University Medical Center | Durham, North Carolina 27710 |
UCLA Medical Center | Los Angeles, California 90095-7059 |
University of Alabama-Birmingham Hospital | Birmingham, Alabama 35249 |
Shands at the University of Florida, Division of Hematology/Oncology | Gainesville, Florida 32610 |
Emory University Hospital | Atlanta, Georgia 30322 |
Dana Farber Cancer Institute Dana 1B11 | Boston, Massachusetts 02115 |
Massachusetts General Hospital Cox Bldg Room 640 | Boston, Massachusetts 02114 |
Beth Israel Deaconess Medical Center KS121 | Brookline, Massachusetts 02215 |
The Nebraska Medical Center | Omaha, Nebraska 68198 |